A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed

Radiotherapy and Oncology

Volumn 112, Issue 2, 2014, Pages 187-193

  Carter, Hannah E ^a   Martin, Andrew ^a   Schofield, Deborah ^a   Duchesne, Gillian ^b   Haworth, Annette ^b,c   Hornby, Colin ^c   Sidhom, Mark ^d   Jackson, Michael ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cost; Decision model; Effectiveness; IMRT; Prostate cancer; Prostatectomy

Indexed keywords

AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE SYSTEM; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY; ADJUVANT THERAPY; AUSTRALIA; COMPUTER ASSISTED RADIOTHERAPY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; PROBABILITY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS;

AUSTRALIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; MARKOV CHAINS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84911002231     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.03.020     Document Type: Article

References (36)

1. Australian Government Medicare Australia. Medicare Group Reports. 2012 25/06/2012 27/06/2012]. Available from: https://www.medicareaustralia.gov.au/statistics/mbs-group.shtml.
2. M. Bolla Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) Lancet 366 2005 572 578
3. T. Wiegel Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96 02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
4. I.J. Thompson Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial JAMA 296 2006 2329 2335
5. S. Nath Toxicity analysis of postoperative image-guided intensity modulated radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 78 2009 435 441
6. Pearson SJ. Ladapo, Prosser L. Intensity modulated radiation therapy (IMRT) for localized prostate cancer. Institute for Clinical and Economic Review (ICER); 2007 [November].
7. S. Hummel Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation Health Technol Asses 14 2010 1 108
8. R.S.S.M. Carr-Hill Assumptions of the QALY procedure Social Sci Med 29 1989 469 477
9. M.F. Drummond Methods for the economic evaluation of health care programs 1997 Oxford University Press Oxford
10. Trans Tasman Radiation Oncology Group, (TROG). The assessment of new radiation oncology technologies and treatments (ANROTAT): Study protocol A (IMRT Post Prostatectomy) Final Report, Newcastle; 2012.
11. Australian Bureau of Statistics (ABS). Life Tables, Australia, 2009-2011. Canberra: Commonwealth of Australia; 2012.
12. P. Iyengar Toxicity associated with postoperative radiation therapy for prostate cancer Am J Clin Oncol 34 2011 611 618
13. A. Goneka Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy Eur Urol 60 2011 1142 1148
14. S. Kim Late gastrointestinal toxicities following radiation therapy for prostate cancer Eur Urol 60 2011 908 916
15. T. Daly Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review) Cochrane Rev 12 2011
16. Medical Services Advisory Committee Funding for new medical technologies and procedures: application and assessment guidelines 2005 Commonwealth of Australia Canberra
17. M. Seshamani, and A. Gray A longitudinal study of the effects of age and time to death on hospital costs J Health Econ 23 2004 217 235
18. Australian Government, Public Sector - Estimated Round 11 (2006-2007) AR-DRG 5.1 Cost Report. Commonwealth of Australia; 2008.
19. Australian Government Department of Health and Ageing Medicare benefits schedule book 2012 Commonwealth of Australia Canberra
20. Australian Government Department of Health and Ageing, Pharmaceutical Benefits Schedule; 2012.
21. Trans Tasman Radiation Oncology Group, TROG 08.03: A phase III trial comparing adjuvant versus salvage radiotherapy for high risk patients post radical prostatectomy (TROG 08.03 RAVES) Version Amendment 1; 2011.
22. G. Van Andel An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer Eur J Cancer 44 2008 2418 2424
23. A. Briggs, K. Claxton, and M. Sculpher Decision modeling for health economic evaluation, ed. 2006 O.U. Press Oxford
24. M. Studenski Potential for dose-escalation in the post-prostatectomy setting with intensity modulated radiation therapy: a dosimetric study using EORTC consensus guidelines for target volume contours Bodine J 3 2010 [article 41]
25. B. Koontz Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy Med Dosim 34 2009 256 260
26. C. Luo Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer Int J Radiat Oncol Biol Phys 66 2006 1253 1262
27. G. Luxton, S. Hancock, and A. Boyer Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate Int J Radiat Oncol Biol Phys 59 2004 267 284
28. A. Konski Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer Int J Radiat Oncol Biol Phys 66 2006 408 415
29. A. Al-Mamgani Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer Int J Radiat Oncol Biol Phys 73 2009 685 691
30. C. King, and D. Kapp Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 71 2008 346 350
31. J.D. Ruben A comparison of out-of-field dose and its constituent components for intensity-modulated radiation therapy versus conformal radiation therapy: implications for carcinogenesis Int J Radiat Oncol Biol Phys 81 2011 1458 1464
32. H. Suit Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects Radiat Res 167 2007 12 42
33. S. Johnson The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 86 2013 554 561
34. D. Sher Cost-effectiveness studies in radiotherapy Expert Rev Pharmacoecon Outcomes Res 10 2010 567 582
35. P. Nguyen Cost implications of the rapid adoption of newer technologies for treating prostate cancer J Clin Oncol 29 2011 1517 1524
36. T. Fleming, and D. DeMets Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 1996